• Video Upgrade in Process
  • Navigating Treatment Failure in CML
  • Diagnosis and Management of Accelerated Phase CML
  • Going Beyond the Cookie-Cutter Approach: Individualizing Therapeutic Decisions in CML
  • SIMPLICITY Study
  • FAQ's

    FAQ Library

    Respected thought leaders answer frequently asked questions on numerous topics across the spectrum of CML assessment and treatment – available in video, audio, and transcript formats.

What's New

Nurse CE
New Section!CNE Programs Available
Navigating Treatment Failure in CML
An Interactive Educational ExperienceStuart L. Goldberg, MD
Supplemental FAQs for Health Care Professionals
Supplemental FAQs for CML Patients
CE Education
Diagnosis and Management of Accelerated Phase CML
B. Douglas Smith, MD, and Jonathan Webster, MD
CE Education
Going Beyond the Cookie-Cutter Approach: Individualizing Therapeutic Decisions in CML
Stuart L. Goldberg, MD; Harry P. Erba, MD, PhD
CE Education
TKI Treatment Failure: What You Need to Know
Stuart L. Goldberg, MD; Karen P. Seiter, MD
Expert Clinical Commentaries – 2015 ASCO Highlights in CML
Exploring Long Term Efficacy and Safety Signatures for TKI Therapies
Jorge Eduardo Cortes, MD
Addressing Clinical Barriers to Improved Care for CML Patients Through Large Community Data Sets: Anticipating Side Effects, Evaluating Cost Effectiveness of Treatment, and the Impact of Treatment Adherence Beliefs, Behaviors and BCR-ABL Mutation Testing on Outcomes
Stuart L. Goldberg, MD
Expert Clinical Commentaries
Monitoring the Patient with Chronic Myelogenous Leukemia
Stuart L. Goldberg, MD
Clinical Trial Highlights in CML
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (SIMPLICITY)
Michael J. Mauro, MD
FAQ Library
What are the efficacy and safety considerations in using ponatinib?
What is the most common reason for treatment failure?
Why should I consider second-generation TKIs as a first-line approach?
How do we recognize treatment failure or treatment resistance?
Karen P. Seiter, MD